Sequenom (SQNM) surged 9.4% today after a Wedbush analyst said results for its Maternit21 fetal...
Sequenom (SQNM) surged 9.4% today after a Wedbush analyst said results for its Maternit21 fetal genetic tests make it harder to argue that investors should short the stock. “SQNM has effectively met development and commercial launch milestones in the last 12 months and has driven significant test volume in the first six months of launch," the firm says.
From other sites
at CNBC.com (Dec 3, 2014)
at CNBC.com (Jan 14, 2014)
at CNBC.com (Mar 15, 2013)
at CNBC.com (Apr 25, 2012)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs